

A new self-rating scale for detecting atypical or second-effects

Journal of Psychopharmacology

22, 238-243

DOI: [10.1177/0269881107087976](https://doi.org/10.1177/0269881107087976)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Evaluating Treatment. , 0, , 169-188.		1
3	First-generation antipsychotic long-acting injections <i>v</i>. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies. British Journal of Psychiatry, 2009, 195, s20-s28.	1.7	89
4	Antipsychotic long-acting injections in clinical practice: Medication management and patient choice. British Journal of Psychiatry, 2009, 195, s51-s56.	1.7	36
7	Attitudes of patients and mental health staff to antipsychotic long-acting injections: Systematic review. British Journal of Psychiatry, 2009, 195, s43-s50.	1.7	87
8	Systematic Evaluation of Rating Scales for Drug-Induced Parkinsonism and Recommendations for Future Research. Journal of Clinical Psychopharmacology, 2010, 30, 57-63.	0.7	28
9	Incorporating Evidence From Pharmacologic and Pharmacogenetic Studies of Atypical Antipsychotic Drugs Into Advanced Psychiatric Nursing Practice. Perspectives in Psychiatric Care, 2010, 46, 98-107.	0.9	4
10	Managing medications in schizophrenia. Practice Nursing, 2010, 21, 393-396.	0.1	4
11	The use of Enhancing Quality Use of Medication Self-Reported Questionnaire (EQUIM-SRQ) among mental health consumers: a pilot study. Australasian Psychiatry, 2012, 20, 327-332.	0.4	2
12	Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of headâ€head comparisons. Journal of Psychopharmacology, 2012, 26, 15-26.	2.0	60
13	Module 12. Achieving concordance in the treatment of bipolar disorder. NursePrescribing, 2012, 10, 1-7.	0.1	0
14	Monitoring and documentation of side effects from depot antipsychotic medication: an interdisciplinary audit of practice in a regional mental health service. Journal of Psychiatric and Mental Health Nursing, 2012, 19, 395-401.	1.2	9
15	A brief version of the Subjects' Response to Antipsychotics questionnaire to evaluate treatment effects. Schizophrenia Research, 2013, 147, 175-180.	1.1	11
16	Physical health checks for people with severe mental illness. Primary Health Care, 2013, 23, 24-26.	0.0	3
17	Psychosis and schizophrenia: a mental health nurse's perspective. NursePrescribing, 2013, 11, 505-509.	0.1	1
18	Prescribing quetiapine using a medications management framework. NursePrescribing, 2014, 12, 81-86.	0.1	0
19	Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Related Outcome Measures, 2014, 5, 43.	0.7	396
20	SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. Therapeutic Advances in Psychopharmacology, 2014, 4, 15-21.	1.2	36
21	A review of self-report medication side effect questionnaires for mental health patients. Psychiatry Research, 2014, 219, 664-673.	1.7	12

#	ARTICLE	IF	CITATIONS
22	A cluster randomised controlled trial and process evaluation of a training programme for mental health professionals to enhance user involvement in care planning in service users with severe mental health issues (EQUIP): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 348.	0.7	20
23	Screening for incontinence in a secure psychiatric service for women. <i>International Journal of Mental Health Nursing</i> , 2015, 24, 451-459.	2.1	4
24	Construction and validation of the My Medicines and Me Questionnaire for assessment of the self-reported side effects of psychotropic medication. <i>International Clinical Psychopharmacology</i> , 2015, 30, 224-229.	0.9	4
25	<i>â€œFirst do no harm.â€ A systematic review of the prevalence and management of antipsychotic adverse effects. <i>Journal of Psychopharmacology</i> , 2015, 29, 353-362.	2.0	165
26	Glasgow Antipsychotic Side-effects Scale for Clozapine â€” Development and validation of a clozapine-specific side-effects scale. <i>Schizophrenia Research</i> , 2015, 168, 505-513.	1.1	46
27	Rating scales to measure side effects of antipsychotic medication: A systematic review. <i>Journal of Psychopharmacology</i> , 2015, 29, 857-866.	2.0	31
28	Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 863.	1.8	85
29	Lay health supporters aided by a mobile phone messaging system to improve care of villagers with schizophrenia in Liuyang, China: protocol for a randomised control trial. <i>BMJ Open</i> , 2016, 6, e010120.	0.8	20
30	Monitoring antipsychotic side effects: a competed audit cycle conducted in a secure hospital. <i>Journal of Forensic Practice</i> , 2016, 18, 182-188.	0.2	0
31	Mental health nursesâ€™ views about antipsychotic medication side effects. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2016, 23, 369-377.	1.2	6
32	Antipsychotic medication side effect assessment tools: A systematic review. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 399-409.	1.3	21
33	What side effects are problematic for patients prescribed antipsychotic medication? The Maudsley Side Effects (MSE) measure for antipsychotic medication. <i>Psychological Medicine</i> , 2017, 47, 2369-2378.	2.7	21
34	Academic detailing among psychiatrists â€” feasibility and acceptability. <i>International Journal of Health Care Quality Assurance</i> , 2017, 30, 79-88.	0.2	2
35	Survey of antipsychotic medication curriculum content in Australian university nursing programmes. <i>International Journal of Mental Health Nursing</i> , 2017, 26, 56-64.	2.1	3
36	Augmentation of aripiprazole by flupenthixol decanoate in poorly responsive schizophrenia: a randomized clinical study. <i>Journal of Theoretical Social Psychology</i> , 2017, 27, 235-242.	1.2	0
37	A tolerability burden index in schizophrenia: incorporating patient perspective in clinical trial adverse event reporting. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1372026.	0.8	2
38	Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial. <i>EBioMedicine</i> , 2017, 26, 138-145.	2.7	58
39	Efficacy and Tolerability of Clozapine versus Quetiapine in Treatment-resistant Schizophrenia. <i>Indian Journal of Psychological Medicine</i> , 2017, 39, 770-776.	0.6	13

#	ARTICLE	IF	CITATIONS
40	Eliciting adverse effects data from participants in clinical trials. The Cochrane Library, 2018, 2018, MR000039.	1.5	21
41	Australian mental health nurses'™ perspectives about the identification and management of antipsychotic medication side effects: a cross-sectional survey. Journal of Mental Health, 2018, 27, 23-29.	1.0	3
42	Effective assessment of psychotropic medication side effects using PsyLOG mobile application. Schizophrenia Research, 2018, 192, 211-212.	1.1	6
43	Translation and cultural adaptation of Glasgow Antipsychotic Side-effects Scale (GASS) in Arabic. PLoS ONE, 2018, 13, e0201225.	1.1	7
44	Embedding shared decision-making in the care of patients with severe and enduring mental health problems: The EQUIP pragmatic cluster randomised trial. PLoS ONE, 2018, 13, e0201533.	1.1	33
45	A pilot study examining the profile of older people on clozapine. Australasian Psychiatry, 2018, 26, 619-623.	0.4	0
46	Patterns of Prescription of Psychotropic Medications and Their Adherence among Patients with Schizophrenia in Two Psychiatric Hospitals in Accra, Ghana: A Cross-Sectional Survey. Psychiatry Journal, 2018, 2018, 1-10.	0.7	8
47	Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi. BMC Research Notes, 2019, 12, 376.	0.6	4
48	Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study. BMC Psychiatry, 2019, 19, 32.	1.1	15
49	Attitude towards Antipsychotic Medications in Patients Diagnosed with Schizophrenia: A Cross-Sectional Study at Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia. Schizophrenia Research and Treatment, 2019, 2019, 1-9.	0.7	7
50	Paliperidone Long-Acting Injections in Huntington's™ Disease for Motor and Behavioural Disturbances. Clinical Drug Investigation, 2019, 39, 407-410.	1.1	5
51	Unravelling subjectivity, embodied experience and (taking) psychotropic medication. Social Science and Medicine, 2019, 230, 66-73.	1.8	13
52	<p>Mediating Effect Of The Motivation For Medication Use On Disease Management And Medication Adherence Among Community-Dwelling Patients With Schizophrenia</p>. Patient Preference and Adherence, 2019, Volume 13, 1877-1887.	0.8	10
53	The influence of adherence to antipsychotics medication on the quality of life among patients with schizophrenia in Indonesia. Perspectives in Psychiatric Care, 2019, 55, 147-152.	0.9	10
54	Common Data Elements for National Institute of Mental Health's™ Funded Translational Early Psychosis Research. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 10-22.	1.1	2
55	Check the effects: systematic assessment of antipsychotic side-effects in an inpatient cohort. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532095711.	1.2	11
56	The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey. Annals of General Psychiatry, 2020, 19, 42.	1.2	33
57	Supervised treatment in outpatients for schizophrenia plus (STOPS+): protocol for a cluster randomised trial of a community-based intervention to improve treatment adherence and reduce the treatment gap for schizophrenia in Pakistan. BMJ Open, 2020, 10, e034709.	0.8	3

#	ARTICLE	IF	CITATIONS
58	INTREPID II: protocol for a multistudy programme of research on untreated psychosis in India, Nigeria and Trinidad. <i>BMJ Open</i> , 2020, 10, e039004.	0.8	12
59	Pennsylvania coordinated specialty care programs for first-episode psychosis: 6- and 12-month outcomes. <i>Microbial Biotechnology</i> , 2020, 15, 1395-1408.	0.9	6
60	Monitoring cardiovascular disease risk in individuals with severe mental illness in an inpatient mental health setting: a secondary data analysis. <i>British Journal of Mental Health Nursing</i> , 2020, 9, 1-14.	0.1	3
61	Good Clinical Practice in Psychopharmacology. , 2020, , 203-203.		0
62	Clinical validation of the self-reported Glasgow Antipsychotic Side-effect Scale using the clinician-rated UKU side-effect scale as gold standard reference. <i>Journal of Psychopharmacology</i> , 2020, 34, 820-828.	2.0	12
63	Reliability of the Glasgow Antipsychotic Side-effects Scale for Clozapine Japanese version (GASS-C-J). <i>PLoS ONE</i> , 2020, 15, e0234864.	1.1	2
64	Antipsychotic choice: understanding shared decision-making among doctors and patients. <i>Journal of Mental Health</i> , 2021, 30, 66-73.	1.0	6
65	Establishing a physical health monitoring service for patients on depot antipsychotic medication. <i>Irish Journal of Psychological Medicine</i> , 2021, 38, 16-22.	0.7	4
66	Side-effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532199127.	1.2	1
67	Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview. <i>Journal of Psychopharmacology</i> , 2021, 35, 1081-1090.	2.0	9
68	A Prospective Evaluation of Structures and Processes Associated with the Quality of Mental Health Care in the Kingdom of Saudi Arabia. <i>The Saudi Journal of Health Systems Research</i> , 2021, 1, 51-66.	0.5	0
69	Psychotropic medicine beliefs, side effects and adherence in schizophrenia: a patient-caregiver dyad perspective. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 1370-1380.	1.0	0
70	Lifetime relapse and its associated factors among people with schizophrenia spectrum disorders who are on follow up at Comprehensive Specialized Hospitals in Amhara region, Ethiopia: a cross-sectional study. <i>International Journal of Mental Health Systems</i> , 2021, 15, 42.	1.1	14
71	Mediating effect of empowerment on the relationship between global function and personal recovery among community-dwelling patients with schizophrenia: a cross-sectional study. <i>BMC Psychiatry</i> , 2021, 21, 241.	1.1	2
72	Atypical antipsychotics: Managing adverse effects. <i>Perspectives in Psychiatric Care</i> , 2021, , .	0.9	3
73	Syndromes extrapyramidaux induits par les médicaments. <i>NPG Neurologie - Psychiatrie - Geriatrie</i> , 2022, 22, 25-34.	0.1	1
74	Developing an International Standard Set of Patient-Reported Outcome Measures for Psychotic Disorders. <i>Psychiatric Services</i> , 2022, 73, 249-258.	1.1	13
75	Antipsychotic-placebo separation on the PANSS-6 subscale as compared to the PANSS-30: a pooled participant-level analysis. <i>NPJ Schizophrenia</i> , 2021, 7, 41.	2.0	6

#	ARTICLE	IF	CITATIONS
76	Antipsychotic Side-Effect Rating Scales in Schizophrenia. , 2012, , 45-53.		1
77	Acceptability and tolerability of omega-3 fatty acids as adjunctive treatment for children and adolescents with eating disorders. <i>Eating Disorders</i> , 2017, 25, 114-121.	1.9	10
78	Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation) <i>Tj ETQqO 0 0 rg0Ts/Overl0k 10 Tf 50</i>	0.1	1
79	Mobile Texting and Lay Health Supporters to Improve Schizophrenia Care in a Resource-Poor Community in Rural China (LEAN Trial): Randomized Controlled Trial Extended Implementation. <i>Journal of Medical Internet Research</i> , 2020, 22, e22631.	2.1	9
80	A Mobile Health Platform for Clinical Monitoring in Early Psychosis: Implementation in Community-Based Outpatient Early Psychosis Care. <i>JMIR Mental Health</i> , 2018, 5, e15.	1.7	66
81	Training to enhance user and carer involvement in mental health-care planning: the EQUIP research programme including a cluster RCT. <i>Programme Grants for Applied Research</i> , 2019, 7, 1-140.	0.4	8
82	Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study. <i>Indian Journal of Medical Research</i> , 2016, 144, 697.	0.4	11
83	Using the STARTER model to talk about sex in mental health nursing practice. <i>Mental Health Practice</i> , 2020, 23, 32-41.	0.1	3
85	Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in Greece. <i>Journal of Psychology & Clinical Psychiatry</i> , 2014, 1, .	0.0	1
88	Identification of Antipsychotic Side Effects with Glassgow Antipsychotic Side-Effect Scale (GASS). <i>Journal of Health Science and Prevention</i> , 2020, 4, 85-90.	0.1	0
90	Pseudo-Resistant Schizophrenia: Non-Adherence to Treatment. <i>Korean Journal of Schizophrenia Research</i> , 2020, 23, 51-57.	0.3	0
91	Improving physical health in people with severe mental illness. <i>Practice Nursing</i> , 2020, 31, 456-460.	0.1	1
92	Monitoring cardiovascular disease risk in individuals with severe mental illness in an inpatient mental health setting: a secondary data analysis. <i>British Journal of Cardiac Nursing</i> , 2020, 15, 1-15.	0.0	1
93	Patient-Reported Questionnaires to Identify Adverse Drug Reactions: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11877.	1.2	5
95	Residual Effect of Texting to Promote Medication Adherence for Villagers with Schizophrenia in China: 18-Month Follow-up Survey After the Randomized Controlled Trial Discontinuation. <i>JMIR MHealth and UHealth</i> , 2022, 10, e33628.	1.8	1
96	Development of empirically derived brief program evaluation measures in Pennsylvania first-episode psychosis coordinated specialty care programs. <i>Microbial Biotechnology</i> , 2022, , .	0.9	0
97	Clinical validation of the Aarhus Side effect Assessment Questionnaire(ASAQ). <i>Journal of Psychopharmacology</i> , 2022, 36, 507-515.	2.0	3
98	Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in an Italian Sample of Patients with Stable Schizophrenia and Bipolar Spectrum Disorders. <i>Brain Sciences</i> , 2022, 12, 891.	1.1	1

#	ARTICLE	IF	CITATIONS
99	Barriers to the management of sexual dysfunction among people with psychosis: analysis of qualitative data from the REMEDY trial. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	3
100	E-Prevention: Advanced Support System for Monitoring and Relapse Prevention in Patients with Psychotic Disorders Analyzing Long-Term Multimodal Data from Wearables and Video Captures. <i>Sensors</i> , 2022, 22, 7544.	2.1	11
101	Collaborative Prescribing and Advanced Mental Health Nursing Practice. , 2022, , 335-356.		0
102	Shared decision-making interventions for people with mental health conditions. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	6
103	Utilizing questionnaires for medication counselling of patients taking antipsychotics during the COVID-19 pandemic: a single site, community pharmacy-based survey study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2022, 8, .	0.4	0
104	Experimental Approaches and Generating the Evidence. , 2023, , 1-17.		0
105	Behavioural activation for depressive symptoms in young people with emerging or early psychosis: A pilot study protocol. <i>PLoS ONE</i> , 2023, 18, e0280559.	1.1	1
106	Comparative effects of clozapine and risperidone monotherapy on levels of immunoglobulins in patients with schizophrenia – A 12 weeks' longitudinal study. <i>Journal of Mental Health and Human Behaviour</i> , 2022, 27, 119.	0.3	0
107	Systematic Review of Psychotropic Adverse Drug Event Monitoring Tools for Use in Long-Term Care Facilities. <i>Journal of the American Medical Directors Association</i> , 2023, , .	1.2	0
108	Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. <i>Movement Disorders</i> , 2023, 38, 1008-1026.	2.2	2
113	Experimental Approaches and Generating the Evidence. , 2023, , 721-736.		0